Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
0 likes 2mo
Access · International · continued
Prescription portability between countries posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
c.niemel, post #42: Taking post #41 at face value and following it one step further. Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging. Go to post
Prescription portability between countries sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Everything in post #59 holds. The case it does not cover is the one I have.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
That is one dataset and I would not build a rule on it.
5 likes 1mo
Narrowing post #63, because the general version has more than one answer.
Prescription portability between countries is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
0 likes 1mo
a.kwiatkowski, post #52: The reason prescription portability between countries is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent. Go to post
Worth separating two things that post #63 runs together.
An honest declaration on prescription portability between countries: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
g.oyelaran, post #38: Saving this. It is the version I will quote when the question comes round again. Go to post
This is the sort of exchange that makes the archive worth searching.
The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.
A single observation, in a thread that deserves better than single observations.
2 likes 1mo
Post #67 answers the question as asked. The question underneath it is different.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
I would be glad to be shown a cleaner way of putting this.
0 likes 1mo
Where I part company with post #67, and it is a narrow parting.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
Take the reasoning and check the arithmetic; I do not always get it right.
21 likes 1mo
Post #67 is the version of this I will quote in future. One addition.
Where the prescription portability between countries reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
9 likes 1mo
Collapsed as off-topic by two members at trust level 3 or above
Answering the prescription portability between countries question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
0 likes 1mo
Confirming post #70 from a second method, which matters more than confirming it from a second person.
Comparing prices across countries without accounting for what is included — device, needles, dispensing — produces comparisons that are not comparisons.
Noting that I have skin in this question and have tried to discount for it.
7 likes 1mo
a.kwiatkowski, post #52: The reason prescription portability between countries is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent. Go to post
Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.
A weak preference rather than a position.
Adding a data point of agreement rather than a data point.
0 likes 1mo
The question underneath prescription portability between countries is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
1 like 1mo
Post #74 is right about the mechanism and I think understates the practical bit.
I would put moderate confidence on the mainstream reading of prescription portability between countries and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
12 likes 1mo
r.mwangi, post #47: Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page. It is a small point and it changes the answer, which is an awkward combination. Go to post
Coming back to post #76, because the follow-up matters more than the original answer.
Customs practice varies between entry points within the same country, which is why two people in the same jurisdiction report different experiences honestly.
That is where I would start, not where I would stop.
Taking post #78 at face value and following it one step further.
Reciprocal recognition between regulators exists in some regions and not others, and assuming it is how people end up surprised.
One more caveat and then I will stop qualifying: the sample selected itself.
0 likes 30d
Collapsed as off-topic by two members at trust level 3 or above
Post #76 and I disagree about the size of the effect, not about the direction.
If someone has run prescription portability between countries properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
Filing this under things that are true until someone shows me otherwise.
16 likes 29d
This follows post #81 rather than contradicting it.
Before the thread moves on from prescription portability between countries — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
6 likes 28d
h.mukherjee, post #26: Post #23 is the version of this I will quote in future. One addition. Posting my prescription portability between countries numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer. Go to post
Coming back to post #81, because the follow-up matters more than the original answer.
Worth separating prescription portability between countries as a question about the compound from prescription portability between countries as a question about the documentation. They get answered by different people and only one of them is answerable here.
Comparing prices across countries without accounting for what is included — device, needles, dispensing — produces comparisons that are not comparisons.
If this contradicts something upthread, the upthread version may well be the better one.
0 likes 26d
s.chowdhury, post #19: Confirming post #16 from a second method, which matters more than confirming it from a second person. The most useful reply I ever got about prescription portability between countries was a request to state my units. It sounds like pedantry and it has saved me twice. Go to post
I read post #85 twice before replying, because I had assumed the opposite.
Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
Post #85 answers the question as asked. The question underneath it is different.
On prescription portability between countries: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
32 likes 23d
Post #85 describes the usual case. This is about the unusual one.
Source for the prescription portability between countries figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.
Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.
7 likes 22d
integrator_log, post #39: Post #37 is the version of this I will quote in future. One addition. Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change. Go to post
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
If that is already documented somewhere, ignore me and link it.